Lipum attends the largest Nordic Partnering Conference

- This is the right arena for Lipum, says Einar Pontén. It gives us an opportunity to meet people and inform about our progress and long-term plan.

Lipum will participate September 10-12th at Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry.

The NLSDays attracts leading decision makers from biotech, pharma and medtech as well as finance, research, policy and regulatory authorities.

About Us

Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.

Subscribe

Media

Media